Boehringer Ingelheim Day with MassBio

Boehringer Ingelheim Day with MassBio

2:00 – 7:30pm

MassBio and Catalyst restaurant at 300 Technology Square, Cambridge, MA 02139

October 8th, 2015


The Indiana Health Industry Forum has been invited to submit member profiles for consideration in the Boehringer Ingelheim Pharma Days program.  This event will be held in Boston, October 8th and is organized by MassBio – IHIF’s counterpart organization in Massachusetts.  If you would like to be considered for a one-on-one meeting with Boehringer Ingelheim, please submit a one-pager describing your program of interest to Kristin Jones at IHIF ( by September 30th.  Please do not disclose confidential information. If selected, you must be able to travel to Boston on October 8th to participate in the meetings.


Please join us on Thursday, October 8th, 2015 for a private meeting and reception with a select group of MassBio members and senior leaders from Boehringer Ingelheim.

Boehringer Ingelheim will provide an overview of its Research & Development organization, Venture fund, therapeutic areas of interest and models for early and late stage licensing partnerships. There will be an opportunity to request one–to-one meetings. A poster competition and pitch contest will take place and a networking reception will follow the program. An innovation prize will be awarded to the winning start-up from the pitch contest at the reception.

One-on-one meetings may be requested by participants.

Boehringer Ingelheim will have teams within the following areas participating in one-on-one meetings: CNS, Oncology, Cardiometabolic, Immunology, Respiratory, Hearing loss, Microbiome, Regenerative medicine and Gene medicine.  For more details, see list below.


2:00 – 3:00pm               Registration and Poster presentation vote for Innovation Prize

Attendees will receive Massbio Dollars to invest into the top 3 most innovative technologies presented.


3:00 – 3:05pm               Welcome by MassBio Robert K. Coughlin, President and CEO at MassBio


3:05 – 3:30pm            Boehringer Ingelheim Partnering – Working Together for Better Health

  • Paola Casarosa, Corp VP, Business Development & Licensing/ Prescription Medicines


3:30 – 4:00pm            Discovery Research and External Innovation

  • Clive Wood, Corp Senior VP, Discovery Research


4:00 – 4:30pm            Boehringer Ingelheim Corporate Venture Fund

  • Frank Kalkbrenner, VP, Head of the Boehringer Ingelheim Venture Fund


4:30 – 5:00pm               Innovation Prize pitches and judging


5:00 – 5:30pm               Boehringer Ingelheim closing remarks and Q&A


5:30 –7:00pm                Reception – Catalyst
Innovation Prize winner will be announced at the reception


This event, part of the MassBio Pharma Day Series, will provide a great opportunity to network with Boehringer Ingelheim licensing and therapeutic area leaders and learn how a biopharmaceutical company evaluates external research and approaches licensing and partnerships.


Current Areas of Interest:


    • Central Nervous System
  • Alzheimer’s disease
  • Schizophrenia (focus: negative symptoms and/or cognitive impairment)
  • Depression (focus: treatment-resistant depression)
  • Impulse control disorders

Out of scope: Monoamine uptake inhibitors or monoamine receptor modulators, Compounds with undefined mechanism of action

    • Oncology
  • For clinical stage opportunities: Focus on lung cancer and haematology – irrespective of the MoA
  • Up to IND-ready stage:
  • Cancer cell -directed therapies
    • Growth signaling
    • Apoptosis regulation
    • Epigenetic regulation
    • Protein homeostasis
    • Additional areas of focus will emerge from scientific breakthroughs in cancer biology (e.g. genome integrity, splicing, protein translation, stem cell / developmental pathways, miRNAs)
  • Immune cell -directed therapies
    • Immune cell re-activation
    • Immune cell re-direction
    • Immune cell priming
    • Increased focus in the future will be on lymphocyte trafficking


  • Immunology
    • Crohn’s disease and ulcerative colitis
    • Systemic lupus erythematosus (including lupus nephritis)
    • Rheumatologic disorders such as RA (limited to mechanisms that show superior efficacy compared to current standard of care) and spondyloarthritis
    • Systemic sclerosis-scleroderma

Out of Scope: Microbial therapeutics and Gene therapy


  • Cardiometabolic
    • Chronic Kidney Diseases and Diabetic Nephropathy
    • Diabetic Retinopathy
    • NASH (Nonalcoholic steatohepatitis) and liver fibrosis
    • Obesity (CV-benefit and patient relevant weight loss >10%)
    • Type 2 Diabetes (evidence for disease modification, CV-risk reduction and/or significant weight reduction)


  • Respiratory
    • Chronic Obstructive Pulmonary Disease
    • Asthma
    • Interstitial Pulmonary Fibrosis
    • Cystic Fibrosis
    • Acute Lung Injury or Acute Respiratory Distress Syndrome


  • Research Beyond Borders
  • Microbiome:
    • Novel bacteria/bacterial products and their causal role in human health & disease (esp. related to autoimmune, CNS, oncology  and cardiometabolic disorders)
    • Microbiome triggers which impact host immune/inflammatory response & barrier function Depression (focus: treatment-resistant depression)
    • Elucidation of associated pathways & discrete targets (both host & microbiome-derived) for therapeutic intervention
  • Regenerative Medicine:
    • Molecular understanding of mechanisms involved in tissue degeneration
    • New targets or methods for identifying targets that are implicated in the mobilization and/or differentiation of endogenous stem cells/progenitor cells
    • Approaches that may modulate muscle/bone/cartilage degeneration, and/or neurodegeneration
  • Gene Therapy:
    • Rare diseases with high unmet medical need as entry, enabling BI to become a leader in the field; including proprietary assets available for potential partnering
    • Technology platform development, focusing on inducible system for regulatable expression of therapeutic products in the context of AAVs, ensuring applicability of gene therapies in nonlife-threatening diseases
  • Hearing Loss:
    • Understanding of mechanisms involved in hearing loss and approaches with potential to restore hearing or reduce loss
  • Age-related, as well as noise and drug-induced hearing loss




Boehringer Ingelheim Attendees:


Dr. Paola Casarosa, Corp. VP, Bus. Dev. & Licensing/Prescription Medicines

Dr. Monica Cheng, Global Licensing, Cardiometabolic Diseases, Bus. Dev. & Licensing/Prescription Medicines

Dr. Laurie Churchill, Global Head Immunology, Bus. Dev. & Licensing/Prescription Medicines

Dr. Henri Doods, VP, Research Beyond Borders

Dr. Jay Fine, Vice President & Global Therapeutic Area Head Immunology and Respiratory Diseases Research

Dr. Christine Grygon, Executive Director, Bus. Dev. & Licensing/Prescription Medicines

Dr. Martin Heidecker, Head of Venture Fund USA

Dr. Jullian Jones, Global Licensing, Oncology

Dr. Frank Kalkbrenner, VP, Venture Fund

Dr. Cyrille Kuhn, Executive Director, Head of Research Beyond Borders

Dr. Michael Mark, Global Head CardioMetabolic Diseases Research

Dr. Klaus Mendla, Global Head CNS, Bus. Dev. & Licensing/Prescription Medicines

Mr. Imran Nasrullah, Innovation Sourcing, Bus. Dev. & Licensing/Prescription Medicines

Dr. Chad Nivens, Global Head Respiratory, Bus. Dev. & Licensing/Prescription Medicines

Mr. Andrew Owenson, Corp. SVP, Therapeutic Area Head Respiratory

Dr. Michel Pairet, Corp. SVP, R&D non-clinical

Dr. Glyn Parkin, Corp. SVP, Therapeutic Area Head Cardiometabolic Diseases

Dr. Mark Pearson, VP, New Therapeutics Concept Discovery

Dr. Jan Poth, Therapeutic Area Head Immunology & Vice President Marketing, Pipeline Products

Mr. Ralph Mark, Director, External Partnerships and Financial Strategy

Dr. Juergen Reess, Therapeutic Area Head CNS

Dr. Oliver Reuss, Head of Business Model & HealthCare Innovation

Dr. Ioannis Sapountzis, Global Head Oncology, Bus. Dev. & Licensing/Prescription Medicines

Prof. Dr. Gerd Schnorrenberg, Senior Executive Advisor, R&D non-clinical

Dr. Margrit Schwarz, VP, Cardiometabolic Diseases Research

Dr. Peter Seither, Senior Manager, Scientific Collaborations

Dr. Bernd Sommer, Head of CNS Research

Dr. Georg van Husen, Therapeutic Area Head Cardiovascular

Dr. Clive Wood, Corp. SVP, Discovery Research

Dr. Johannes Zanzinger, Global Head Cardiometabolic Diseases, Bus. Dev. & Licensing/Prescription Medicines



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: